Biopharmaceutical companies are developing over 200 medicines for heart disease and stroke, which are leading causes of death. Medicines have already helped reduce deaths from these diseases by 30% from 2001-2011. The new medicines in development use various technologies and approaches, and are in clinical trials or under FDA review. Despite progress, heart disease and stroke remain major health challenges, costing over $300 billion per year and affecting millions of Americans.
Cardiovascular Therapeutic Area: Trends, Developments & Clinical Data Managem...Vinayak Thorat
This presentation will give overview on Trends, Developments in Cardiovascular Therapeutic Area; Opportunities in the field of Clinical Data Management
Heparin-Induced Thrombocytopenia (HIT) is a highly prothrombotic disorder mediated by strong platelet-activating antibodies against multi molecular complexes of platelet factor4 and heparin, leading to consumptive thrombocytopenia and potentially devastating thromboembolic complications. Three alternative anticoagulants have been approved for the treatment of HIT: lepirudin, argatroban, and danaparoidsodium. We present a case of multiple organ embolism secondary to heparin-induced thrombocytopenia after IABP insertion in a cardiac shock secondary to acute myocardial infarction and our fi rst experience with the use of a novel oral anticoagulant, rivaroxaban, to treat a case of HIT-associated thrombosis after IABP insertion.
Cardiovascular Therapeutic Area: Trends, Developments & Clinical Data Managem...Vinayak Thorat
This presentation will give overview on Trends, Developments in Cardiovascular Therapeutic Area; Opportunities in the field of Clinical Data Management
Heparin-Induced Thrombocytopenia (HIT) is a highly prothrombotic disorder mediated by strong platelet-activating antibodies against multi molecular complexes of platelet factor4 and heparin, leading to consumptive thrombocytopenia and potentially devastating thromboembolic complications. Three alternative anticoagulants have been approved for the treatment of HIT: lepirudin, argatroban, and danaparoidsodium. We present a case of multiple organ embolism secondary to heparin-induced thrombocytopenia after IABP insertion in a cardiac shock secondary to acute myocardial infarction and our fi rst experience with the use of a novel oral anticoagulant, rivaroxaban, to treat a case of HIT-associated thrombosis after IABP insertion.
Although many are still concerned with an ARB–MI paradox, our study of close to 60 000 patients with MI should serve as reassurance that ARBs are not associated with adverse outcomes compared with ACEIs. Potential benefits of ARBs as compared with ACEIs in older women with MI should be further evaluated.
What are anti-coagulants?
What are the difference between antiplatelet, anticoagulants and thrombolytics?
Coagulation cascade
Virchows Triad
Classification of anti-coagulants?
Indications of anti-coagulants?
Mechanism and site of action of different anti-coagulants?
2015 Report: Medicines in Development for Heart Disease & StrokePhRMA
According to the American Heart Association, someone in the United States dies from cardiovascular disease every 40 seconds, and more than 85 million Americans have at least one form of the disease. Heart disease has been the leading cause of death in the United States since 1921, but these numbers are declining. Read this report by PhRMA - in partnership with the Association of Black Cardiologists - on the nearly 200 medicines in development for heart disease & stroke.
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
Comparative effectives of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers added to standard medical therapy for treating patients with stable ischemic heart disease and preserved left ventricular systolic function.
Although many are still concerned with an ARB–MI paradox, our study of close to 60 000 patients with MI should serve as reassurance that ARBs are not associated with adverse outcomes compared with ACEIs. Potential benefits of ARBs as compared with ACEIs in older women with MI should be further evaluated.
What are anti-coagulants?
What are the difference between antiplatelet, anticoagulants and thrombolytics?
Coagulation cascade
Virchows Triad
Classification of anti-coagulants?
Indications of anti-coagulants?
Mechanism and site of action of different anti-coagulants?
2015 Report: Medicines in Development for Heart Disease & StrokePhRMA
According to the American Heart Association, someone in the United States dies from cardiovascular disease every 40 seconds, and more than 85 million Americans have at least one form of the disease. Heart disease has been the leading cause of death in the United States since 1921, but these numbers are declining. Read this report by PhRMA - in partnership with the Association of Black Cardiologists - on the nearly 200 medicines in development for heart disease & stroke.
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
Comparative effectives of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers added to standard medical therapy for treating patients with stable ischemic heart disease and preserved left ventricular systolic function.
2014 Report: Medicines in Development for Older AmericansPhRMA
As life expectancy continues to climb—up to more than 81 years for women and 76 years for men—the growing number of Americans age 65 and older will face new challenges from chronic conditions such as arthritis, Alzheimer’s disease, cardiovascular disease and diabetes, which impact their health, productivity and independence. Those diseases not only impact the individuals living with them, but burden their families and cost the health care system billions of dollars.
Biopharmaceutical research companies are developing 435 medicines targeting 15 leading chronic conditions affecting seniors—Alzheimer’s and dementia, anemia, arthritis, benign prostatic hyperplasia, cataracts and glaucoma, chronic
kidney disease, chronic obstructive pulmonary disease (COPD), depression, diabetes, heart failure, hyperlipidemia,
hypertension, hypothyroidism and ischemic heart disease.
Prescription Medicines Costs in Context - June 2019PhRMA
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
Prescription Medicines - Insulin Costs in ContextPhRMA
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released naturally in the body and more effectively managing the disease. The options available today also help meet a wide range of unmet needs, providing patients with the tools necessary to stay adherent and healthy – saving costs throughout the health care system. However, this innovation isn’t enough if patients can’t afford their insulin and other medicines at the pharmacy.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Heart 2013
1. 2013REPORT
Biopharmaceutical research companies
are developing 215 medicines for two of
the leading causes of death in Ameri-
cans—heart disease and stroke. Medi-
cines have helped cut deaths from these
diseases by 30 percent between 2001
and 2011, and in 2008 stroke dropped to
the fourth leading cause of death after
being the third for more than 50 years.
This progress is in large part due to
innovative medicines.
Despite this progress, heart disease and
stroke persist as key public health chal-
lenges. According to the American Heart
Association, every 39 seconds an Ameri-
can dies from cardiovascular disease, and
more than 83 million Americans have
at least one type of the disease. These
diseases cost our society more than $312
billion a year.
The medicines in development include:
30 for heart failure, 29 for lipid disorders
(such as high cholesterol), 19 for stroke,
and 17 each for high blood pressure and
ischemic disorders. Many of the potential
medicines use cutting-edge technologies
and new scientific approaches, such as:
• A gene therapy that uses a patient’s
own cells to treat heart failure.
• A medicine that blocks the transfer of
good (HDL) cholesterol to bad (LDL).
• A genetically-engineered medicine that
dissolves clots to treat stroke.
All of the medicines are either in clinical
trials or awaiting review by the Food and
Drug Administration. A glossary of terms
begins on page 24. Links to sponsor
company websites provide more informa-
tion on the potential products.
For information on the current innovative
products in the pipeline for cardiovascular
disease and the value of medicines for
patients and our healthcare system, please
see Medicines in Development for Heart
Disease and Stroke 2013—Overview.
Biopharmaceutical Research Companies Are
Developing More Than 200 Medicines for
Cardiovascular Disease
Medicines in Development
Heart Disease and Stroke
A Report on Cardiovascular Disease
presented by america’s biopharmaceutical research companies
LipidDisorders
Hypertension
30
17 17
IschemicDisorders
29
HeartFailure
Stroke
19
Application
Submitted
Phase III
Phase II
Phase I
Medicines in Development
For Heart Disease and Stroke
83.6 Million
Americans Suffer
From Cardiovascular
Disease
More Than
700,000
Die Each Year
2. Medicines in Development Heart Disease and Stroke 20132
Medicines in Development for Heart Disease and Stroke
*For more information about a specific medicine or company in the report, please click on the provided link.
Acute Coronary Syndrome
Product Name Sponsor Indication Development Phase*
cangrelor The Medicines Company
Parsippany, NJ
acute coronary syndrome
(see also coronary artery disease,
thrombosis)
Phase I
www.themedicinescompany.com
CER-001
(recombinant HDL)
CerenisTherapeutics
Ann Arbor, MI
acute coronary syndrome
(see also lipid disorders)
Phase II
www.cerenis.com
gevokizumab Servier
Paris, France
XOMA
Berkeley, CA
acute coronary syndrome Phase II
www.servier.com
www.xoma.com
inclacumab
(RG1512)
Roche
Nutley, NJ
acute coronary syndrome
(see also heart attack, peripheral
vascular disease)
Phase II
www.roche.com
losmapimod
(p38 kinase inhibitor)
GlaxoSmithKline
Rsch. Triangle Park, NC
acute coronary syndrome Phase II
www.gsk.com
PF-06282999 Pfizer
New York, NY
acute coronary syndrome Phase I
www.pfizer.com
REG1
(anivamersen-pegnivacogin
intravenous)
Regado Biosciences
Basking Ridge, NJ
acute coronary syndrome Phase II
www.regadobio.com
RVX-208
(BET protein inhibitor)
Resverlogix
Calgary, Canada
acute coronary syndrome
(see also atherosclerosis)
Phase II
www.resverlogix.com
vorapaxar
(thrombin/PAR-1 receptor
antagonist)
Merck
Whitehouse Station, NJ
acute coronary syndrome
(prevention) (FastTrack)
(see also thrombosis)
Phase III
www.merck.com
VT-111a VironTherapeutics
Ontario, Canada
acute coronary syndrome Phase II
www.vironinc.com
Vytorin®
ezetimibe/simvastatin
fixed-dose combination
Merck
Whitehouse Station, NJ
acute coronary syndrome Phase III
www.merck.com
Xarelto®
rivaroxaban
Bayer HealthCare Pharmaceuticals
Wayne, NJ
Janssen Research Development
Raritan, NJ
acute coronary syndrome
(FastTrack)
(see also thrombosis, other)
application submitted
www.bayerpharma.com
www.janssenrnd.com
3. Medicines in Development Heart Disease and Stroke 2013 3
Medicines in Development for Heart Disease and Stroke
Adjunctive Therapies, Revascularization
Product Name Sponsor Indication Development Phase
ATryn®
antithrombin
(recombinant)
(Orphan Drug)
rEVO Biologics
Framingham, MA
heparin resistance in patients
undergoing coronary artery bypass
graft (CABG) surgery
(see also hypertension)
--------------------------------------
heparin resistance in patients
undergoing CABG surgery in
neonates
Phase III
www.gtc-bio.com
-----------------------------------------
Phase I
www.gtc-bio.com
CMX-2043
(proto-oncogene protein C
AKT modulator)
Ischemix
Maynard, MA
prevention of ischemia-reperfusion
injury in patients undergoing
percutaneous coronary
intervention (PCI)
Phase II
www.ischemix.com
myolimus-eluting stent Elixir Medical
Sunnyvale, CA
coronary artery restenosis
(prevention)
Phase I
www.elixirmedical.com
novolimus-eluting coronary stent Elixir Medical
Sunnyvale, CA
coronary artery restenosis
(prevention)
in clinical trials
www.elixirmedical.com
PRT-201 ProteonTherapeutics
Waltham, MA
vascular access for hemodialysis
(see also peripheral vascular
disease)
Phase II
www.proteontherapeutics.com
ranolazine Gilead Sciences
Foster City, CA
incomplete revascularization
in patients who undergo PCI
Phase III
www.gilead.com
sirolimus-eluting coronary stent REVA Medical
San Diego, CA
coronary artery restenosis in clinical trials
www.teamreva.com
sirolimus-eluting coronary stent Svelte Medical Systems
New Providence, NJ
ischemic heart disorder Phase I/II
www.sveltemedical.com
SRM003
(endothelial cell therapy)
Shire Pharmaceuticals
Wayne, PA
prevention of peripheral vascular
complications in patients
undergoing arteriovenous access
procedures for hemodialysis
Phase II
www.shire.com
4. Medicines in Development Heart Disease and Stroke 20134
Medicines in Development for Heart Disease and Stroke
Arrhythmia, Atrial Fibrillation
Product Name Sponsor Indication Development Phase
ARM036 ARMGO Pharma
Tarrytown, NY
catecholaminergic polymorphic
ventricular tachycardia type 1
(see also heart failure)
Phase II
www.armgo.com
azimilide Forest Laboratories
New York, NY
ventricular arrhythmia Phase III
www.frx.com
BMS-919373
(Ikur antagonist)
Bristol-Myers Squibb
Princeton, NJ
atrial fibrillation Phase I
www.bms.com
danegaptide
(ZP1609)
Zealand Pharma
Copenhagen, Denmark
atrial fibrillation Phase I
www.zealandpharma.com
GS-6615
(sodium channel antagonist)
Gilead Sciences
Foster City, CA
arrhythmia
(see also ischemic disorders)
Phase I
www.gilead.com
ISIS-CRPRx
(C-reactive protein inhibitor)
Isis Pharmaceuticals
Carlsbad, CA
paroxysmal atrial fibrillation Phase I
www.isispharm.com
OPC-108459 Otsuka America Pharmaceutical
Rockville, MD
paroxysmal and persistent atrial
fibrillation
Phase I
www.otsuka.com
ranolazine/dronedarone
fixed-dose combination
Gilead Sciences
Foster City, CA
paroxysmal atrial fibrillation Phase II
www.gilead.com
vanoxerine ChanRx
Cleveland, OH
atrial fibrillation Phase II
www.chanrx.com
vernakalant
(oral)
Cardiome Pharma
Vancouver, Canada
atrial fibrillation Phase II
www.cardiome.com
Atherosclerosis
Product Name Sponsor Indication Development Phase
ACP-501
(rhLCAT)
AlphaCore Pharma
Ann Arbor, MI
atherosclerosis
(see also coronary artery disease)
Phase I
www.alphacorepharma.com
ACZ885
(canakinumab)
Novartis Pharmaceuticals
East Hanover, NJ
atherosclerosis in patients with
type 2 diabetes
(see also other)
Phase II
www.novartis.com
anacetrapib
(MK-0859)
Merck
Whitehouse Station, NJ
atherosclerosis
(see also lipid disorders)
Phase III
www.merck.com
BMS-852927
(LXR modulator)
Bristol-Myers Squibb
Princeton, NJ
atherosclerosis Phase I
www.bms.com
5. Medicines in Development Heart Disease and Stroke 2013 5
Medicines in Development for Heart Disease and Stroke
Atherosclerosis
Product Name Sponsor Indication Development Phase
BMS-962476
(PCSK9 adnectin)
Bristol-Myers Squibb
Princeton, NJ
atherosclerosis Phase I
www.bms.com
CSL-112
(cholesterol modulator)
CSL
Victoria, Australia
atherosclerosis Phase II
www.csl.com.au
darapladib
(Lp-PLA2 inhibitor)
GlaxoSmithKline
Rsch. Triangle Park, NC
atherosclerosis Phase III
www.gsk.com
ISIS-APOARx
(antisense RNA inhibitor)
Isis Pharmaceuticals
Carlsbad, CA
atherosclerosis Phase I
www.isispharm.com
rilapladib GlaxoSmithKline
Rsch. Triangle Park, NC
atherosclerosis Phase II completed
www.gsk.com
RVX-208
(BET protein inhibitor)
Resverlogix
Calgary, Canada
atherosclerosis
(see also acute coronary syndrome)
Phase II
www.resverlogix.com
Tekturna®
aliskiren
Novartis Pharmaceuticals
East Hanover, NJ
atherosclerosis in coronary
artery disease
(see also heart failure,
hypertension)
Phase III
www.novartis.com
VB201
(IL-12 subunit p40 inhibitor)
VBLTherapeutics
Or Yehuda, Israel
atherosclerosis Phase II
www.vblrx.com
Coronary Artery Disease
Product Name Sponsor Indication Development Phase
ACP-501
(rhLCAT)
AlphaCore Pharma
Ann Arbor, MI
coronary artery disease
(see also atherosclerosis)
Phase I
www.alphacorepharma.com
cangrelor The Medicines Company
Parsippany, NJ
coronary artery disease in patients
requiring percutaneous coronary
intervention (PCI)
(see also acute coronary syndrome,
thrombosis)
Phase III
www.themedicinescompany.com
cardiovascular therapy
releasing balloon
(drug-coated Angiosculpt®)
AngioScore
Fremont, CA
coronary artery restenosis Phase II
www.angioscore.com
coronary artery disease
gene therapy
BioCardia
San Carlos, CA
coronary artery disease Phase II
www.biocardia.com
6. Medicines in Development Heart Disease and Stroke 20136
Medicines in Development for Heart Disease and Stroke
Coronary Artery Disease
Product Name Sponsor Indication Development Phase
fibroblast growth factor-1 (FGF-1) CardioVascular BioTherapeutics
Las Vegas, NV
severe coronary heart disease Phase II
www.cvbt.com
LT-1951
(oligo-L-arginine)
LumenTherapeutics
Menlo Park, CA
coronary artery restenosis Phase I/II
www.lumentherapeutics.com
pradigastat
(LCQ908)
Novartis Pharmaceuticals
East Hanover, NJ
coronary artery disease
(see also lipid disorders)
Phase II
www.novartis.com
RG7652
(PCSK9 protein inhibitor)
Genentech
South San Francisco, CA
coronary heart disease Phase II
www.gene.com
Heart Attack (Myocardial Infarction)
Product Name Sponsor Indication Development Phase
abciximab
(intracoronary infusion)
Atrium Medical Corporation
Hudson, NH
myocardial infarction
(new delivery system)
Phase III
www.atriummed.com
adipose-derived regenerative cell
(ADRC) therapy
CytoriTherapeutics
San Diego, CA
acute myocardial infarction
(see also ischemic disorders)
Phase II
www.cytori.com
AMR-001
(stem cell therapy)
Amorcyte (NeoStem)
New York, NY
myocardial infarction Phase I
www.neostem.com
BB3
(HGF mimetic)
Angion Biomedica
Uniondale, NY
acute myocardial infarction Phase II
www.angion.com
Brilinta®
ticagrelor
AstraZeneca
Wilmington, DE
prior myocardial infarction
(see also peripheral vascular
disease)
Phase III
www.astrazeneca.com
CAP-1002
(allogeneic cardiosphere-derived
stem cell therapy)
Capricor
Beverly Hills, CA
myocardial infarction Phase I/II
www.capricor.com
inclacumab Roche
Nutley, NJ
myocardial infarction
(see also acute coronary syndrome,
peripheral vascular disease)
Phase II
www.roche.com
ischemic tolerant allogeneic
mesenchymal stem cell therapy
Stemedica CellTechnologies
San Diego, CA
acute myocardial infarction Phase II
www.stemedica.com
mesenchymal stem cell therapy Mesoblast
New York, NY
heart attack
(see also heart failure)
Phase II
www.mesoblast.com
7. Medicines in Development Heart Disease and Stroke 2013 7
Medicines in Development for Heart Disease and Stroke
Heart Attack (Myocardial Infarction)
Product Name Sponsor Indication Development Phase
MultiStem®
stem cell therapy
Athersys
Cleveland, OH
acute myocardial infarction
(see also stroke)
Phase I completed
www.athersys.com
NEU 2000 GNT Pharma
Yongin, South Korea
myocardial infarction
(see also stroke)
Phase I completed
www.gntpharma.com
Prochymal®
remestemcel-L
OsirisTherapeutics
Columbia, MD
acute myocardial infarction Phase II
www.osiris.com
Heart Failure (Congestive Heart Failure)
Product Name Sponsor Indication Development Phase
albiglutide
(GSK716155)
GlaxoSmithKline
Rsch. Triangle Park, NC
heart failure Phase II completed
www.gsk.com
ANX-042
(natriuretic-peptide)
Anexon
Cambridge, MA
acute decompensated heart failure Phase I
www.anexonrx.com
ARM036 ARMGO Pharma
Tarrytown, NY
chronic heart failure
(see also arrhythmia)
Phase II
www.armgo.com
BAY 868050
(vasopressin receptor antagonist)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
heart failure Phase I
www.bayerpharma.com
BAY 948862
(mineralocorticoid receptor [MR]
antagonist)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
chronic heart failure Phase II
www.bayerpharma.com
BAY 1021189
(guanylate cyclase stimulant)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
heart failure Phase I
www.bayerpharma.com
BAY 1067197
(partial adenosine A1 agonist)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
heart failure Phase I
www.bayerpharma.com
BMS-986046
(PEG-relaxin)
Ambrx
La Jolla, CA
Bristol-Myers Squibb
Princeton, NJ
heart failure Phase I
www.ambrx.com
www.bms.com
bucindolol companion diagnostic ARCA biopharma
Broomfield, CO
LabCorp
Burlington, NC
heart failure (diagnosis) in clinical trials
www.arcabiopharma.com
www.labcorp.com
8. Medicines in Development Heart Disease and Stroke 20138
Medicines in Development for Heart Disease and Stroke
cenderitide NileTherapeutics
San Mateo, CA
acute heart failure
(FastTrack)
--------------------------------------
chronic heart failure
(FastTrack)
Phase II
www.nilethera.com
-----------------------------------------
Phase I
www.nilethera.com
CLP-1001
(sodium-potassium-chloride
symporter inhibitor)
SorbentTherapeutics
Sunnyvale, CA
congestive heart failure in patients
with chronic kidney disease
Phase II
www.sorbent.com
CXL-1020
(nitroxyl donor)
Cardioxyl Pharmaceuticals
Chapel Hill, NC
acute decompensated heart failure Phase II
www.cardioxyl.com
Gencaro™
bucindolol
ARCA biopharma
Broomfield, CO
genotype-defined heart failure
(FastTrack)
application submitted
www.arcabiopharma.com
GGF2
(recombinant neuregulin-1)
AcordaTherapeutics
Ardsley, NY
heart failure
(FastTrack)
Phase I
www.acorda.com
GSK2849466
(selective androgen receptor
modulator)
GlaxoSmithKline
Rsch. Triangle Park, NC
heart failure Phase I
www.gsk.com
JNJ-39588146 Janssen Research Development
Raritan, NJ
heart failure Phase II
www.janssenrnd.com
JVS-100
(stromal cell-derived factor-1)
JuventasTherapeutics
Cleveland, OH
heart failure
(see also ischemic disorders)
Phase II
www.juventasinc.com
LCZ696
(ARB/NEP inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
heart failure
(see also hypertension)
Phase III
www.novartis.com
mesenchymal stem cell therapy Mesoblast
New York, NY
congestive heart failure
(see also heart attack)
Phase II
www.mesoblast.com
Mydicar®
SERCA 2a gene therapy
Celladon
San Diego, CA
advanced (Class III/IV) heart failure
(FastTrack)
--------------------------------------
chronic heart failure
Phase II
www.celladon.net
-----------------------------------------
Phase II completed
www.celladon.net
MyoCell®
stem cell therapy
Bioheart
Sunrise, FL
heart failure Phase II/III
www.bioheartinc.com
MyoCell® SDF1
muscle stem cell therapy
(second-generation)
BioHeart
Sunrise, FL
congestive heart post myocardial
infarction
Phase I
www.bioheartinc.com
Heart Failure (Congestive Heart Failure)
Product Name Sponsor Indication Development Phase
9. Medicines in Development Heart Disease and Stroke 2013 9
Medicines in Development for Heart Disease and Stroke
omecamtiv mecarbil Amgen
Thousand Oaks, CA
Cytokinetics
South San Francisco, CA
heart failure Phase II
www.amgen.com
www.cytokinetics.com
PL-3994
(natriuretic-peptide)
PalatinTechnologies
Cranbury, NJ
congestive heart failure
(see also hypertension)
Phase II
www.palatin.com
recombinant human
neuregulin-1 beta
Zensun
Shanghai, China
stable chronic heart failure Phase II
www.zensun.com
serelaxin
(RLX030)
Novartis Pharmaceuticals
East Hanover, NJ
acute heart failure
(FastTrack)
--------------------------------------
chronic heart failure
Phase III
www.novartis.com
-----------------------------------------
Phase II
www.novartis.com
Tekturna®
aliskiren
Novartis Pharmaceuticals
East Hanover, NJ
acute decompensated heart failure
(see also atherosclerosis,
hypertension)
--------------------------------------
reduction of cardiovascular death/
hospitalization in chronic heart
failure patients
Phase III completed
www.novartis.com
-----------------------------------------
Phase III
www.novartis.com
TRV027
(angiotensin type 1 receptor
antagonist)
Forest Laboratories
New York, NY
Trevena
King of Prussia, PA
acute heart failure
(late-stage disease)
Phase II
www.frx.com
www.trevenainc.com
ularitide Cardiorentis
Zug, Switzerland
acute heart failure Phase III
www.cardiorentis.ch
urocortin 2 Neurocrine Biosciences
San Diego, CA
congestive heart failure Phase II
www.neurocrine.com
Hypertension (High Blood Pressure)
Product Name Sponsor Indication Development Phase
AHU377
(neprilysin inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
essential hypertension Phase II
www.novartis.com
ATryn®
antithrombin
(recombinant)
rEVO Biologics
Framingham, MA
preeclampsia
(see also adjunctive therapies)
Phase II
www.gtc-bio.com
Heart Failure (Congestive Heart Failure)
Product Name Sponsor Indication Development Phase
10. Medicines in Development Heart Disease and Stroke 201310
Medicines in Development for Heart Disease and Stroke
candesartan cilexetil/nifedipine
fixed-dose combination
Bayer HealthCare Pharmaceuticals
Wayne, NJ
essential hypertension Phase III
www.bayerpharma.com
digoxin immune Fab (DIF)
(Orphan Drug)
Glenveigh Pharmaceuticals
Chattanooga, TN
preeclampsia
(FastTrack)
Phase II
www.glenveigh.com
Edarbi®
azilsartan medoxomil
Takeda Pharmaceuticals
Deerfield, IL
hypertension (pediatric) Phase I
www.takeda.com
GSK2944406
(amlodipine/losartan
fixed-dose combination)
GlaxoSmithKline
Rsch. Triangle Park, NC
hypertension Phase I
www.gsk.com
HL-040XC
(atorvastatin/losartan
fixed-dose combination)
HanAll Biopharma
Seoul, South Korea
hypertension
(see also lipid disorders)
Phase II
www.hanall.co.kr
HT-101
(amiloride/spironolactone)
HemodynamicTherapeutics
Durham, NC
obesity-related resistant
hypertension
Phase II
www.hemodynamictx.com
KD027
(PDE5 inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
hypertension Phase I
www.kadmon.com
LCZ696
(ARB/NEP inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
essential hypertension
(see also heart failure)
Phase II
www.novartis.com
MK-7145 Merck
Whitehouse Station, NJ
hypertension Phase I completed
www.merck.com
MK-8150 Merck
Whitehouse Station, NJ
hypertension Phase I
www.merck.com
nebivolol/valsartan
fixed-dose combination
Forest Laboratories
New York, NY
essential hypertension Phase III
www.frx.com
PB1046
(Vasomera)
PhaseBio Pharmaceuticals
Malvern, PA
essential hypertension Phase I/II
www.phasebio.com
perindopril/amlodipine
fixed-dose combination
XOMA
Berkeley, CA
hypertension Phase III
www.xoma.com
PL-3994
(natriuretic-peptide)
PalatinTechnologies
Cranbury, NJ
hypertension
(see also heart failure)
Phase II
www.palatin.com
Tekturna®
aliskiren
Novartis Pharmaceuticals
East Hanover, NJ
hypertension in children age
6-17 years of age
(see also atherosclerosis, heart
failure)
Phase III
www.novartis.com
Hypertension (High Blood Pressure)
Product Name Sponsor Indication Development Phase
11. Medicines in Development Heart Disease and Stroke 2013 11
Medicines in Development for Heart Disease and Stroke
99m-Tc-EC-G CellPoint
Centennial, CO
myocardial ischemia (diagnosis) Phase II
www.cellpointweb.com
Amiscan™
Tc-99m-glucarate
MolecularTargetingTechnologies
West Chester, PA
acute coronary syndrome
(diagnosis)
Phase II
www.mtarget.com
BFPET™
(myocardial perfusion imaging
agent)
FluoroPharma
Montclair, NJ
coronary artery disease (diagnosis) Phase I
www.fluoropharma.com
CardioPET™
cardiac PET imaging agent
FluoroPharma
Montclair, NJ
coronary artery disease (diagnosis) Phase II
www.fluoropharma.com
fluorine-18-ML-10 IBA Molecular US
Dulles, VA
stroke (diagnosis) Phase II
www.iba-molecular.com
flurpiridaz F-18 Lantheus Medical Imaging
N. Billerica, MA
coronary artery disease (diagnosis) Phase III
www.lantheus.com
Imagify™
perflubutane
Acusphere
Lexington, MA
coronary artery disease (diagnosis) Phase III
www.acusphere.com
LMI 1195
(PET imaging agent)
Lantheus Medical Imaging
N. Billerica, MA
heart failure (diagnosis) Phase I
www.lantheus.com
ThromboView®
Tc-99m 3B6/22 anti-fibrin mAb
AGEN Biomedical
(Agenix)
Victoria, Australia
deep vein thrombosis (diagnosis),
pulmonary thrombosis (diagnosis)
Phase II
www.agenix.com
Ischemic Disorders
Product Name Sponsor Indication Development Phase
ACY001
(autologous AC133+ selected adult
bone marrow-derived stem cell
therapy)
Compass Biomedical
Cleveland, OH
chronic coronary ischemia Phase I
www.compassbiomedical.com
adipose-derived regenerative cell
(ADRC) therapy
CytoriTherapeutics
San Diego, CA
chronic myocardial ischemia
(see also heart attack)
Phase I/II
www.cytori.com
Imaging Agents
Product Name Sponsor Indication Development Phase
12. Medicines in Development Heart Disease and Stroke 201312
Medicines in Development for Heart Disease and Stroke
Ischemic Disorders
Product Name Sponsor Indication Development Phase
ALD-201
(bone marrow-derived adult
stem cell therapy)
Cytomedix
Gaithersburg, MD
ischemic heart failure Phase I
www.cytomedix.com
ALD-301
(bone marrow-derived adult
stem cell therapy)
Cytomedix
Gaithersburg, MD
critical limb ischemia Phase I/II
www.cytomedix.com
ALO212
(stem cell therapy)
Compass Biomedical
Cleveland, OH
critical limb ischemia Phase I
www.compassbiomedical.com
allogeneic/autologous adult
mesenchymal stem cell therapy
BioCardia
San Carlos, CA
ischemic heart disorder Phase I/II
www.biocardia.com
autologous stem cell therapy Baxter Healthcare
Deerfield, IL
myocardial ischemia Phase III
www.baxter.com
Bendavia™
mitochondrial-targeting
short peptide
Stealth Peptides
Newtown Centre, MA
ischemic reperfusion in acute
myocardial infarction and heart
failure
Phase II
www.stealthpeptides.com
Collategene®
beperminogene perplasmid
(HGF plasmid)
AnGes
Bethesda, MD
MitsubishiTanabe Pharma America
Jersey City, NJ
------------------------------------------------
AnGes
Bethesda, MD
critical limb ischemia
(FastTrack)
--------------------------------------
ischemic heart disorder
Phase III
www.anges-mg.com
www.mt-pharma-america.com
-----------------------------------------
Phase I
www.anges-mg.com
ERC-124
(endometrial blood stem cell
therapy)
MediStem
San Diego, CA
critical limb ischemia in clinical trials
www.medisteminc.com
Generx®
alferminogene tadenovec
(Ad5FGF-4)
CardiumTherapeutics
San Diego, CA
myocardial ischemia
(FastTrack)
Phase III
www.cardiumthx.com
GS-6615
(sodium channel antagonist)
Gilead Sciences
Foster City, CA
ischemic heart disease
(see also arrhythmia)
Phase I
www.gilead.com
JVS-100
(stromal cell-derived factor-1)
JuventasTherapeutics
Cleveland, OH
critical limb ischemia
(see also heart failure)
Phase II
www.juventasinc.com
MESENDO
combination autologous
stem cell therapy
TCA CellularTherapy
Covington, LA
coronary ischemia, lower limb
ischemia
Phase II
www.tcacellulartherapy.com
13. Medicines in Development Heart Disease and Stroke 2013 13
Medicines in Development for Heart Disease and Stroke
Ischemic Disorders
Product Name Sponsor Indication Development Phase
MP4OX Sangart
San Diego, CA
ischemia Phase II completed
www.sangart.com
PLX-PAD
(stem cell therapy)
PluristemTherapeutics
Haifa, Israel
critical limb ischemia
(see also peripheral vascular
disease)
Phase I
www.pluristem.com
VM202
(modified hepatocyte growth
factor gene therapy)
ViroMed
Seoul, South Korea
myocardial ischemia
(see also peripheral vascular
disease)
Phase I
www.viromed.co.kr
Lipid Disorders
Product Name Sponsor Indication Development Phase
ALN-PCS
(PCSK9 protein inhibitor)
Alnylam Pharmaceuticals
Cambridge, MA
The Medicines Company
Parsippany, NJ
hypercholesterolemia Phase I
www.alnylam.com
www.themedicinescompany.com
AMG 145
(PCSK9 inhibitor mAb)
Amgen
Thousand Oaks, CA
heterozygous familial
hypercholesterolemia,
hypercholesterolemia
Phase I
www.amgen.com
AMR-102
(icosapent ethyl/statin
fixed-dose combination)
Amarin
Bedminster, NJ
hyperlipidemia Phase I
www.amarincorp.com
anacetrapib
(MK-0859)
Merck
Whitehouse Station, NJ
heterozygous familial
hypercholesterolemia,
hypercholesterolemia
(see also atherosclerosis)
Phase III
www.merck.com
ARI-3037MO
(niacin analog)
Arisaph Pharmaceuticals
Boston, MA
dyslipidemia Phase I
www.arisaph.com
CAT-2003
(eicosapentaenoic acid/niacin)
Catabasis Pharmaceuticals
Cambridge, MA
severe hypertriglyceridemia Phase I
www.catabasis.com
14. Medicines in Development Heart Disease and Stroke 201314
Medicines in Development for Heart Disease and Stroke
Lipid Disorders
Product Name Sponsor Indication Development Phase
CER-001
(recombinant HDL)
CerenisTherapeutics
Ann Arbor, MI
homozygous familial
hypercholesterolemia
(see also acute coronary syndrome)
Phase II
www.cerenis.com
CER-002
(PPAR-delta agonist)
CerenisTherapeutics
Ann Arbor, MI
dyslipidemia with low HDL Phase I
www.cerenis.com
CER-627
(low flushing niacin)
CerenisTherapeutics
Ann Arbor, MI
dyslipidemia with low HDL Phase I
www.cerenis.com
diazoxide choline
controlled-release
Essentialis
Carlsbad, CA
hypertriglyceridemia Phase II
www.essentialistherapeutics.com
Epanova™
eicosapentaenoic acid/
docosahexaenoic acid
Omthera Pharmaceuticals
Princeton, NJ
hypertriglyceridemia
(combination therapy)
--------------------------------------
hypertriglyceridemia
(monotherapy)
Phase III
www.omthera.com
-----------------------------------------
Phase II/III
www.omthera.com
ETC-1002
(ATP citrate [pro-S]-lyase inhibitor/
adenylate kinase stimulator)
EsperionTherapeutics
Plymouth, MI
dyslipidemia Phase II
www.esperion.com
fenofibrate/simvastatin
fixed-dose combination
AbbVie
North Chicago, IL
hyperlipidemia Phase III
www.abbvie.com
GSK1292263
(bombesin receptor agonist)
GlaxoSmithKline
Rsch. Triangle Park, NC
hyperlipidemia Phase II completed
www.gsk.com
HL-040XC
(atorvastatin/losartan
fixed-dose combination)
HanAll Biopharma
Seoul, South Korea
hyperlipidemia
(see also hypertension)
Phase II
www.hanall.co.kr
HPP593
(PPAR-delta agonist)
High Point Pharmaceuticals
High Point, NC
dyslipidemia Phase I
www.highpointpharma.com
ISIS-APOCIIIRx
(apolipoprotein C-III inhibitor)
Isis Pharmaceuticals
Carlsbad, CA
hypertriglyceridemia Phase I
www.isispharm.com
K-877
(PPAR-alpha agonist)
Kowa Pharmaceuticals America
Montgomery, AL
dyslipidemia Phase I
www.kowa.co.jp
KD026
(MTP inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
dyslipidemia Phase II
www.kadmon.com
Kynamro®
mipomersen
Genzyme
Cambridge, MA
severe homozygous familial
hypercholesterolemia
Phase III
www.genzyme.com
15. Medicines in Development Heart Disease and Stroke 2013 15
Medicines in Development for Heart Disease and Stroke
Lipid Disorders
Product Name Sponsor Indication Development Phase
MBX-8025
(PPAR-delta agonist)
Metabolex
Hayward, CA
dyslipidemia Phase II
www.metabolex.com
MGL-3196
(liver-directed thyroid hormone
receptor-ß agonist)
Madrigal Pharmaceuticals
Fort Washington, PA
dyslipidemia,
hypercholesterolemia
Phase I
www.madrigalpharma.com
pradigastat
(LCQ908)
Novartis Pharmaceuticals
East Hanover, NJ
familial chylomicronemia
syndrome
(see also coronary artery disease)
--------------------------------------
hypertriglyceridemia
Phase III
www.novartis.com
-----------------------------------------
Phase II
www.novartis.com
RN316
(PF-04950615)
Pfizer
New York, NY
hypercholesterolemia Phase II
www.pfizer.com
RN317
(PF-05335810)
Pfizer
New York, NY
hypercholesterolemia Phase I
www.pfizer.com
SAR236553
(anti-PCSK-9 mAb)
Regeneron Pharmaceuticals
Tarrytown, NY
Sanofi US
Bridgewater, NJ
heterozygous familial
hypercholesterolemia,
hypercholesterolemia
Phase III
www.regeneron.com
www.sanofi.com
SCH-900271 Merck
Whitehouse Station, NJ
hyperlipidemia Phase II completed
www.merck.com
TAP311 Novartis Pharmaceuticals
East Hanover, NJ
dyslipidemia Phase I completed
www.novartis.com
XZK-monascus
(HMG-CoA reductase inhibitor)
Beijing Peking University
WBL Biotech
Beijing, China
hyperlipidemia Phase II
Peripheral Vascular Disease
Product Name Sponsor Indication Development Phase
Benlysta®
belimumab
GlaxoSmithKline
Rsch. Triangle Park, NC
vasculitis Phase III
www.gsk.com
Brilinta®
ticagrelor
AstraZeneca
Wilmington, DE
peripheral arterial disease
(see also heart attack)
Phase III
www.astrazeneca.com
16. Medicines in Development Heart Disease and Stroke 201316
Medicines in Development for Heart Disease and Stroke
Peripheral Vascular Disease
Product Name Sponsor Indication Development Phase
defibrotide Gentium
Villa Guardia, Italy
Sigma-Tau Pharmaceuticals
Gaithersburg, MD
treatment of hepatic venous
occlusive disease after stem cell
transplantation
Phase III
www.gentium.com
www.sigmatau.com
human plasma-derived fibrinolysin Grifols
Barcelona, Spain
peripheral vascular occlusive
disease
Phase I
www.grifols.com
inclacumab Roche
Nutley, NJ
prevention of saphenous vein
graft disease
(see also acute coronary syndrome,
heart attack)
Phase II
www.roche.com
K-134
(PDE3 inhibitor)
Kowa Pharmaceuticals America
Montgomery, AL
arteriosclerosis obliterans Phase II
www.kowa.co.jp
MABp1
(IL-1α mAb)
XBiotech
Austin, TX
vascular restenosis
(FastTrack)
Phase II
www.xbiotech.com
MultiGeneAngio
peripheral arterial disease cell
therapy
MultiGeneVascular Systems
Nesher, Israel
peripheral arterial disease Phase I/II
www.mgvs.co.il
paclitaxel coated balloon Lutonix
Minneapolis, MN
peripheral arterial disease Phase II
www.lutonix.com
paclitaxel-eluting balloon catheter MEDRAD
(Bayer HealthCare)
Warrendale, PA
stenotic peripheral artery lesions application submitted
www.medrad.com
PLX-PAD
(stem cell therapy)
PluristemTherapeutics
Haifa, Israel
intermittent claudication
(see also ischemic disorders)
Phase II
www.pluristem.com
PRT-201 ProteonTherapeutics
Waltham, MA
peripheral arterial disease
(see also adjunctive therapies)
Phase I
www.proteontherapeutics.com
TSC
(trans-sodium crocetinate)
Diffusion Pharmaceuticals
Charlottesville, VA
peripheral arterial disease Phase II completed
www.diffusionpharma.com
TV1001
(sodium nitrite oral)
Theravasc
Cleveland, OH
peripheral arterial disease Phase II
www.theravasc.com
VM202
(modified hepatocyte growth
factor gene therapy)
ViroMed
Seoul, South Korea
peripheral arterial disease
(see also ischemic disorders)
Phase II
www.viromed.co.kr
17. Medicines in Development Heart Disease and Stroke 2013 17
Medicines in Development for Heart Disease and Stroke
Pulmonary Vascular Disease
Product Name Sponsor Indication Development Phase
Adcirca™
tadalafil
Eli Lilly
Indianapolis, IN
pulmonary hypertension
(pediatric)
Phase I/II
www.lilly.com
APD811
(prostanoid receptor agonist)
Arena Pharmaceuticals
San Diego, CA
pulmonary arterial hypertension Phase I
www.arenapharm.com
beraprost 314d
(single isomer version)
UnitedTherapeutics
Silver Spring, MD
pulmonary arterial hypertension Phase II
www.unither.com
DA-8159
(PDE5 inhibitor)
Dong-A Pharmaceutical
Seoul, South Korea
pulmonary arterial hypertension Phase II
en.donga.co.kr
INOmax®
nitric oxide inhalation
(Orphan Drug)
Ikaria
Hampton, NJ
pulmonary arterial hypertension Phase I
www.ikaria.com
Letairis®
ambrisentan
(Orphan Drug)
Gilead Sciences
Foster City, CA
pulmonary hypertension
(pediatric)
Phase II
www.gilead.com
macitentan
(endothelin A receptor antagonist)
(Orphan Drug)
Actelion Pharmaceuticals
South San Francisco, CA
pulmonary arterial hypertension application submitted
www.actelion.com
nitric oxide inhalation GeNO
Waltham, MA
pulmonary arterial hypertension Phase II
www.genollc.com
nitrite inhalation
(Orphan Drug)
Aires Pharmaceuticals
San Diego, CA
pulmonary arterial hypertension Phase II
www.airespharma.com
riociguat Bayer HealthCare Pharmaceuticals
Wayne, NJ
chronic thromboembolic
pulmonary hypertension
application submitted
www.bayerpharma.com
SAR407899
(Rho kinase inhibitor)
Sanofi US
Bridgewater, NJ
pulmonary hypertension Phase I
www.sanofi.com
selexipag Actelion Pharmaceuticals
South San Francisco, CA
pulmonary arterial hypertension Phase III
www.actelion.com
Tracleer®
bosentan
Actelion Pharmaceuticals
South San Francisco, CA
pulmonary arterial hypertension
(pediatric)
Phase III
www.actelion.com
treprostinil (oral)
(sustained-release)
UnitedTherapeutics
Silver Spring, MD
pulmonary arterial hypertension application submitted
www.unither.com
18. Medicines in Development Heart Disease and Stroke 201318
Medicines in Development for Heart Disease and Stroke
Stroke
Product Name Sponsor Indication Development Phase
3K3A-APC
(recombinant human
activated protein C)
ZZ Biotech
Houston, TX
stroke Phase I
www.zzbiotech.com
ALD-401
(bone marrow-derived adult
stem cell therapy)
Cytomedix
Gaithersburg, MD
stroke Phase II
www.cytomedix.com
allogeneic mesenchymal
bone marrow cell therapy
Stemedica CellTechnologies
San Diego, CA
ischemic stroke Phase I/II
www.stemedica.com
Ampyra™
fampridine sustained-release
AcordaTherapeutics
Ardsley, NY
post-stroke deficits Phase II
www.acorda.com
betrixaban Portola Pharmaceuticals
South San Francisco, CA
stroke (prevention) in patients
with atrial fibrillation
(see also thrombosis)
Phase II
www.portola.com
CNTO-0007
(cell therapy)
Janssen Research Development
Raritan, NJ
ischemic stroke Phase I
www.janssenrnd.com
desmoteplase Lundbeck
Deerfield, IL
ischemic stroke
(FastTrack)
Phase III
www.lundbeck.com
GM602
(nervous system modulator)
Genervon Biopharmaceuticals
Pasadena, CA
acute ischemic stroke Phase II
www.genervon.com
GSK249320
(myelin-associated glycoprotein
mAb)
GlaxoSmithKline
Rsch. Triangle Park, NC
stroke Phase II
www.gsk.com
metamfetamine Sinapis Pharma
Jacksonville, FL
stroke Phase I completed
www.sinapispharma.com
MP-124
(PARP inhibitor)
MitsubishiTanabe Pharma America
Jersey City, NJ
acute ischemic stroke Phase I
www.mt-pharma.co.jp
MultiStem®
stem cell therapy
Athersys
Cleveland, OH
stroke
(see also heart attack)
Phase II
www.athersys.com
NA-1
(signal transduction
pathway inhibitor)
NoNO Inc
Toronto, Canada
acute ischemic stroke Phase II completed
www.nonoinc.ca
NEU 2000 GNT Pharma
Yongin, South Korea
stroke
(see also heart attack)
Phase I completed
www.gntpharma.com
19. Medicines in Development Heart Disease and Stroke 2013 19
Medicines in Development for Heart Disease and Stroke
Stroke
Product Name Sponsor Indication Development Phase
PF-03049423 Pfizer
New York, NY
ischemic stroke Phase II
www.pfizer.com
RP-1127
(NCCA-ATP channel inhibitor)
Remedy Pharmaceuticals
New York, NY
stroke Phase II
www.remedypharmaceuticals.com
SAR126119
(TAFIa inhibitor)
Sanofi US
Bridgewater, NJ
acute ischemic stroke Phase I
www.sanofi.com
SB623
(stem cell therapy)
SanBio
Mountain View, CA
stroke Phase I/II
www.san-bio.com
TS01
(recombinant complement
C1-inactivator-protein)
Thrombolytic Science International
Cambridge, MA
stroke Phase I
www.tsillc.net
Thrombosis
Product Name Sponsor Indication Development Phase
betrixaban Portola Pharmaceuticals
South San Francisco, CA
thromboembolism (prevention)
(see also stroke)
Phase III
www.portola.com
cangrelor The Medicines Company
Parsippany, NJ
prevention of coronary thrombosis
prior to coronary artery bypass
graft (CABG)
(see also acute coronary syndrome,
coronary artery disease)
Phase II
www.themedicinescompany.com
clopidogrel intravenous
(MDCO-157)
The Medicines Company
Parsippany, NJ
coronary thrombosis (prevention) Phase III
www.themedicinescompany.com
desirudin IV
(intravenous)
Canyon Pharmaceuticals
Columbia, MD
intravenous bolus-only
administration in patients
undergoing coronary artery
stenting
in clinical trials
www.canyonpharma.com
edoxaban
(oral factor Xa inhibitor)
Daiichi Sankyo
Parsippany, NJ
venous thromboembolism
(prevention), embolism/stroke
in patients with atrial fibrillation
(prevention)
Phase III
www.daiichisankyo.com
20. Medicines in Development Heart Disease and Stroke 201320
Medicines in Development for Heart Disease and Stroke
Eliquis®
apixaban
Bristol-Myers Squibb
Princeton, NJ
Pfizer
New York, NY
prevention of venous
thromboembolism, treatment of
venous thrombosis
Phase III
www.bms.com
www.pfizer.com
GCC-4401 Green Cross
Yongin, South Korea
coronary thrombosis Phase I completed
www.greencross.co.kr
Iprivask®
desirudin SC
(subcutaneous)
Canyon Pharmaceuticals
Columbia, MD
thromboembolism in patients with
suspected heparin-induced
thrombocytopenia (prevention and
treatment), venous
thromboembolism in high-risk
surgical and medical patients
(prevention)
in clinical trials
www.canyonpharma.com
ISIS-FXIRx
(factor XI inhibitor)
Isis Pharmaceuticals
Carlsbad, CA
venous thromboembolism Phase I
www.isispharm.com
Pradaxa®
dabigatran etexilate
Boehringer Ingelheim Pharmaceuticals
Ridgefield, CT
acute treatment and reduction
in the risk of recurrence of deep
venous thrombosis and pulmonary
embolism
Phase III
www.boehringer-ingelheim.com
REG2
(pegnivacogin subcutaneous)
Regado Biosciences
Basking Ridge, NJ
venous thrombosis Phase I
www.regadobio.com
vorapaxar
(thrombin/PAR-1 receptor
antagonist)
Merck
Whitehouse Station, NJ
arterial thrombosis (prevention)
(FastTrack)
(see also acute coronary syndrome)
Phase III
www.merck.com
Xarelto®
rivaroxaban
Bayer HealthCare Pharmaceuticals
Wayne, NJ
Janssen Research Development
Raritan, NJ
venous thromboembolism
(pediatric)
(see also acute coronary syndrome,
other)
Phase I
www.bayerpharma.com
www.janssenrnd.com
Other
Product Name Sponsor Indication Development Phase
ACZ885
(canakinumab)
Novartis Pharmaceuticals
East Hanover, NJ
secondary prevention of
cardiovascular events
(see also atherosclerosis)
Phase III
www.novartis.com
Thrombosis
Product Name Sponsor Indication Development Phase
21. Medicines in Development Heart Disease and Stroke 2013 21
Medicines in Development for Heart Disease and Stroke
aleglitazar
(PPAR alpha/gamma co-agonist)
Roche
Nutley, NJ
prevention of cardiovascular
disorders in patients with type 2
diabetes
Phase III
www.roche.com
ALN-TTRsc
(prealbumin inhibitor)
Alnylam Pharmaceuticals
Cambridge, MA
familial amyloidotic
cardiomyopathy
Phase I
www.alnylam.com
Bydureon®
exenatide extended-release
for injectable suspension
AstraZeneca
Wilmington, DE
Bristol-Myers Squibb
Princeton, NJ
cardiovascular outcomes Phase III
www.astrazeneca.com
www.bms.com
caplacizumab
(Orphan Drug)
Ablynx
Ghent, Belguim
thrombotic thrombocytopenic
purpura
Phase II
www.ablynx.com
CardiaPill®
aspirin/lisinopril/lovastatin
CardioPharma
Wilmington, NC
cardiovascular disorders in clinical trials
www.cardio-pharma.com
cardiovascular disease medicine Eli Lilly
Indianapolis, IN
cardiovascular disease Phase I
www.lilly.com
droxidopa
(Orphan Drug)
ChelseaTherapeutics
Charlotte, NC
orthostatic hypotension
(FastTrack)
application submitted
www.chelseatherapeutics.com
evacetrapib Eli Lilly
Indianapolis, IN
prevention of cardiovascular events
in high-risk vascular disease
Phase III
www.lilly.com
Forxiga®
dapagliflozin
AstraZeneca
Wilmington, DE
Bristol-Myers Squibb
Princeton, NJ
cardiovascular outcomes Phase III
www.astrazeneca.com
www.bms.com
ixmyelocel-T
(stem cell therapy)
Aastrom Biosciences
Ann Arbor, MI
dilated cardiomyopathy Phase II
www.aastrom.com
MEK162
(MEK inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
Noonan syndrome hypertrophic
cardiomyopathy
Phase II
www.novartis.com
Onglyza®
saxagliptin
AstraZeneca
Wilmington, DE
Bristol-Myers Squibb
Princeton, NJ
cardiovascular outcomes Phase III
www.astrazeneca.com
www.bms.com
PA8140
(aspirin 81mg/omeprazole 40mg)
POZEN
Chapel Hill, NC
secondary prevention of
cardiovascular and cerebrovascular
disease in patients at risk for
aspirin-induced ulcers
application submitted
www.pozen.com
Other
Product Name Sponsor Indication Development Phase
23. Medicines in Development Heart Disease and Stroke 2013 23
Glossary
adjunctive therapy—Auxiliary treatment
that is secondary to the main treatment.
angina pectoris—Chest pain, usually
caused by “myocardial ischemia,” a low
supply of oxygen to the heart muscle
resulting from hardening, narrowing,
and sometimes spasm of the coronary
arteries.
application submitted—An application
for marketing has been submitted by the
company to the Food and Drug Admin-
istration (FDA).
arrhythmia—Abnormal heart rhythm,
usually detected by an electrocardio-
gram. Arrhythmias can be caused by
several factors, such as coronary artery
disease, heart valve problems or hyper-
thyroidism.
arteriosclerosis obliterans—An alter-
native term for peripheral vascular
disease.
atherosclerosis—A common disease
in which deposits of plaque containing
calcium and fatty substances, such as
cholesterol, are formed within the inner
layers of the arteries. It is a condition
that progresses over decades, chiefly
affecting the arteries of the heart, brain
and extremities. Its complications include
heart attacks and strokes.
atrial fibrillation—Very fast electrical
discharge patterns that make the heart’s
atria contract extremely rapidly, which
causes the ventricles to contract faster
and less efficiently than normal. As a
result, inadequate amounts of blood are
pumped out of the heart, blood pressure
falls, and heart failure may occur.
bypass graft—A vein or artery graft that
bypasses blockage in an artery.
cardiomyopathy—A type of heart
disease in which the heart muscle is
abnormally enlarged, thickened and/or
stiffened. As a result, the heart muscle’s
ability to pump blood is usually impaired.
cardiovascular—Of or relating to the
heart and blood vessels.
coronary artery disease—A condition
caused by atherosclerosis of the arteries
that supply the heart.
critical limb ischemia (CLI)—CLI is a
severe obstruction of the arteries that
seriously decreases blood flow to the
extremities (arms, hands, legs, feet) and
has progressed to the point of severe
pain and even skin ulcers or sores. The
pain, called “rest pain,” caused by CLI
can wake up a person at night. CLI is
a very severe condition of peripheral
arterial disease and needs comprehen-
sive treatment by a vascular surgeon or
specialist.
deep vein thrombosis—Blood clotting
within the deep-lying veins, often in the
legs or pelvic veins.
dyslipidemia—A condition marked by
abnormal concentrations of lipids or
lipoproteins in the blood.
embolism—The obstruction of a blood
vessel by a foreign substance or a blood
clot. Foreign substances that can cause
embolism include an air bubble, amni-
otic fluid, a globule of fat, a clump of
bacteria, chemicals, and drugs. Blood
clots are the most common cause of
embolism. The term “embolus” refers to
the substance or clot that is obstructing
the blood vessel, while “embolism” refers
to the process by which that happens.
Fast Track—A process designed to
facilitate the development and expedite
the review of drugs to treat serious
diseases and fill an unmet medical need.
The status is assigned by the U.S. Food
and Drug Administration. The purpose
is to get important new drugs to the
patient earlier. Fast Track addresses a
broad range of serious diseases. Gener-
ally, determining factors include whether
the drug will have an impact on such
factors as survival, day-to-day function-
ing, or the likelihood that the disease, if
left untreated, will progress from a less
severe condition to a more serious one.
Filling an unmet medical need is defined
as providing a therapy where none exists
or providing a therapy which may be
potentially superior to existing therapy.
Once a drug receives Fast Track designa-
tion, early and frequent communication
between the FDA and a drug company is
encouraged throughout the entire drug
development and review process. The
frequency of communication assures that
questions and issues are resolved quickly,
often leading to earlier drug approval
and access by patients.
genotype—The genetic constitution
(genome) of a cell, an individual, or an
organism. The genotype of a person is
her or his genetic makeup. It can pertain
to all genes or to a specific gene.
HDL—High-density lipoprotein, some-
times called “good cholesterol.”
heart attack (myocardial infarction)—A
part of the heart muscle (myocardium)
dies as a result of blood and oxygen
deprivation.
heart failure—The end result of many
different types of heart disease. The
heart cannot pump blood out normally.
This results in congestion (water and salt
retention) in the lungs, swelling in the
extremities, and reduced blood flow to
body tissues.
hemodialysis—A medical procedure that
uses a special machine (a dialysis ma-
chine) to filter waste products from the
blood and to restore normal constituents
to it.
hypercholesterolemia—The presence of
an abnormally large amount of cho-
lesterol in the cells and plasma of the
circulating blood.
hyperlipidemia—A group of metabolic
disorders characterized by high levels of
lipids (fatty substances, including choles-
terol) in the blood. Hyperlipidemia is a
risk factor for accelerated atherosclerosis
and premature heart attacks.
hypertension (high blood pressure)—
Persistent elevation of blood pressure
above the normal range while the heart
is in systolic (contracting) or diastolic
(relaxed) mode. Uncontrolled, chronic
24. Medicines in Development Heart Disease and Stroke 201324
Glossary
hypertension strains the heart, damages
arteries and creates a greater risk of
heart attack, stroke and kidney problems.
hypertriglyceridemia—An elevated
triglyceride concentration in the blood.
hypotension—A sudden fall in blood
pressure. It may be caused by hypovo-
lemia resulting from the excessive use
of diuretics, vasodilators, or other types
of drugs, dehydration, or prolonged bed
rest. The disorder may be associated
with Addison’s disease, atherosclerosis
(build-up of fatty deposits in the arter-
ies), diabetes, and certain neurological
disorders. Symptoms, which generally
occur after sudden standing, include diz-
ziness, light-headedness, blurred vision,
and the temporary loss of consciousness.
imaging agent—A substance used to
enhance images of organs and spaces in
the body.
intermittent claudication—The most
prominent symptom of peripheral arte-
rial disease (PAD). It occurs in one-third
to one-half of PAD patients. Claudica-
tion refers to the pain that occurs in PAD
patients when they exercise, particularly
during walking, which is relieved only by
rest. Leg pain occurs in one leg in 40
percent of patients and in both legs in
60 percent of patients.
ischemia—Insufficient supply of blood to
an organ or tissue, which can cause or-
gan damage such as an ischemic stroke.
lipids—A group of fatty substances that
includes triglycerides (the principal forms
of fat in body fat), phospholipids (im-
portant constituents of cell membranes),
and sterols (such as cholesterol).
peripheral vascular disease—The
obstruction of blood supply to the ex-
tremities, particularly the legs, caused by
atherosclerosis.
PET imaging—Positron emission tomog-
raphy.
Phase I—Safety testing and pharmaco-
logical profiling in humans.
Phase II—Effectiveness testing in
humans.
Phase III—Extensive clinical trials in
humans.
preeclampsia—A condition in pregnant
women characterized by high blood
pressure and high levels of protein in
urine.
pulmonary hypertension—High blood
pressure in the arteries supplying the
lungs due to increased resistance to
blood flow through the lungs.
Raynaud’s disease—A circulatory disor-
der caused by insufficient blood supply
to the hands and feet, resulting in cya-
nosis, numbness, pain, and, in extreme
cases, gangrene.
reperfusion injury—Refers to myocar-
dial, vascular, or electro-physiological
dysfunction that is induced by the
restoration of blood flow to previously
ischemic tissue.
restenosis—A condition where an artery
plugs up again following treatment to
open it up.
stent—A metal device that is used to
hold tissue in place. For example, a stent
can keep blood vessels open after a sur-
gical procedure or heart catheterization.
stroke—Usually caused by atheroscle-
rosis. It results in death or serious brain
damage, such as paralysis or loss of
speech. An ischemic stroke is caused
by blocked or narrowed arteries that
prevent sufficient blood and oxygen from
reaching the brain.
thromboembolism—Blockage of a blood
vessel by a fragment that has broken
off and been carried from a thrombus
(blood clot) elsewhere in the circulation.
thrombosis—The formation of a blood
clot within the heart or a blood vessel.
25. The Drug Discovery, Development and Approval Process
The U.S. system of new drug approvals is
perhaps the most rigorous in the world.
It takes 10-15 years, on average, for an experi-
mental drug to travel from lab to U.S. patients,
according to the Tufts Center for the Study of
Drug Development. Only five in 5,000 com-
pounds that enter preclinical testing make it to
human testing. And only one of those five is
approved for sale.
On average, it costs a company $1.2 billion,
including the cost of failures, to get one new
medicine from the laboratory to U.S. patients,
according to a recent study by the Tufts Center
for the Study of Drug Development.
Once a new compound has been identified in
the laboratory, medicines are usually developed
as follows:
Preclinical Testing. A pharmaceutical company
conducts laboratory and animal studies to show
biological activity of the compound against the
targeted disease, and the compound is evalu-
ated for safety.
Investigational New Drug Application (IND).
After completing preclinical testing, a com-
pany files an IND with the U.S. Food and Drug
Administration (FDA) to begin to test the drug
in people. The IND shows results of previous
experiments; how, where and by whom the new
studies will be conducted; the chemical structure
of the compound; how it is thought to work in
the body; any toxic effects found in the animal
studies; and how the compound is manufac-
tured. All clinical trials must be reviewed and ap-
proved by the Institutional Review Board (IRB)
where the trials will be conducted. Progress
reports on clinical trials must be submitted at
least annually to FDA and the IRB.
Clinical Trials, Phase I—Researchers test the
drug in a small group of people, usually between
20 and 80 healthy adult volunteers, to evaluate
its initial safety and tolerability profile, deter-
mine a safe dosage range, and identify potential
side effects.
Clinical Trials, Phase II—The drug is given
to volunteer patients, usually between 100 and
300, to see if it is effective, identify an optimal
dose, and to further evaluate its short-term
safety.
Clinical Trials, Phase III—The drug is given to a
larger, more diverse patient population, often
involving between 1,000 and 3,000 patients
(but sometime many more thousands), to gener-
ate statistically significant evidence to confirm
its safety and effectiveness. They are the lon-
gest studies, and usually take place in multiple
sites around the world.
New Drug Application (NDA)/Biologic License
Application (BLA). Following the completion
of all three phases of clinical trials, a company
analyzes all of the data and files an NDA or BLA
with FDA if the data successfully demonstrate
both safety and effectiveness. The applications
contain all of the scientific information that the
company has gathered. Applications typically
run 100,000 pages or more.
Approval. Once FDA approves an NDA or BLA,
the new medicine becomes available for physi-
cians to prescribe. A company must continue
to submit periodic reports to FDA, including
any cases of adverse reactions and appropriate
quality-control records. For some medicines,
FDA requires additional trials (Phase IV) to
evaluate long-term effects.
Discovering and developing safe and effective
new medicines is a long, difficult, and expensive
process. PhRMA member companies invested an
estimated $48.5 billion in research and develop-
ment in 2012.
Developing a new medicine takes an average of 10-15 years;
For every 5,000-10,000 compounds in the pipeline, only 1 is approved.
The Drug Development and Approval Process
PRE-DISCOVERY
DRUG DISCOVERY PRECLINICAL CLINICAL TRIALS FDA REVIEW LG-SCALE MFG
3 – 6 YEARS 6– 7 YEARS
0.5– 2
YEARS
100–300 1,000–3,00020–80
PHASE
2
PHASE
3
PHASE
1
INDSUBMITTED
NDASUBMITTED
PHASE4:POST-MARKETINGSURVEILLANCE
NUMBER OF VOLUNTEERS
ONE FDA-
APPROVED
DRUG
5,000 –10,000
COMPOUNDS
250 5
Drug Discovery and Development: A LONG, RISKY ROAD